Predicting peptide receptor radionuclide therapy (PRRT) response through the landscape of the immune microenvironment in neuroendocrine tumours

#4481

Introduction: Neuroendocrine tumours (NETs) often have poor prognosis upon metastasis. Peptide receptor radionuclide therapy (PRRT) is a novel treatment leveraging targeted cytotoxicity of radionuclides to efficiently address primary and metastatic tumours of NETs.

Aim(s): The efficacy of PRRT and its beneficial subpopulations remain unclear. Given the link between radionuclide therapy and tumour immunology, we aimed to predict PRRT responsiveness using the tumour immune microenvironment.

Materials and methods: We studied 20 G2-G3 NET patients (primarily originating in the rectum and pancreas) treated with PRRT after first-line therapy progression. Pre-PRRT tumour tissue sections were multicolour stained to reveal baseline immune microenvironment infiltration and spatial landscape and explore its relationship with PRRT response.

Conference:

Presenting Author: Yu J

Authors: Zeng Z, Lu M, Xie Q, Li J, Yang Z,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumour, tumour immune microenvironment, tumour response, therapeutic effect prediction,